Medytox Gains NMPA Approval for NEURAMIS Filler
Medytox said on Sept. 28, that it has obtained product approval from China’s National Medical Products Administration (NMPA) for the hyaluronic acid filler “NEURAMIS Volume Lidocaine.”In addition to “NEURAMIS Deep Lidocaine,” which had previously received product approval in China, Medytox has now a
On September 28, Medytox announced it had received product approval from China's National Medical Products Administration (NMPA) for the hyaluronic acid filler "NEURAMIS Volume Lidocaine." This approval follows the earlier approval of "NEURAMIS Deep Lidocaine," bringing Medytox's lineup of hyaluronic acid fillers to a total of two. Medytox plans to sell "NEURAMIS" in China under the brand name "Fillux."
Developed using Medytox's proprietary technology, NEURAMIS is a hyaluronic acid filler with a residual level of the cross-linking agent BDDE reduced below the standard threshold. This reduction aims to minimize the risk of side effects. The NEURAMIS Volume Lidocaine variant includes lidocaine, a local anesthetic, which helps reduce patients' pain during the procedure. Specifically, NEURAMIS Volume Lidocaine is designed to address facial wrinkles and mid-face volume.
Medytox cited the rapidly growing aesthetic medicine market in China, driven by younger consumers, as a key factor in its expansion. The company also mentioned that while they continue to expand their locally tailored product portfolio, they will engage in follow-up procedures in close collaboration with their partner company. Their goal is to launch products in China by the fourth quarter of the year.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
